Drug Trial Radar · NCT04707261
Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)
Last checked: Nov 19, 2026Latest source record: Jul 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,990
Planned (sponsor's estimate)
Start
Aug 6, 2021
Primary completion
May 5, 2025
Study completion Jan 1, 2026
Sponsor
- Lead sponsor
- Xiangtan Central HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Second Xiangya Hospital of Central South University; ZhuZhou Central Hospital
- First posted
- Jan 13, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to investigate the hemoglobin change and association between hemoglobin change and readmissions due to heart failure, and all-cause death in patients with heart failure treated with dapagliflozin or placebo.
Conditions
- Anemia
- Heart Failure
Interventions
DapagliflozinDrug
Participants will receive dapagliflozin 10 mg once daily
PlaceboDrug
Participants will receive placebo 10 mg once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite number of hospital admissions for Heart Failure (HF) and all-cause deathTime frame: 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Xiangtan Central Hospital
Xiangtan, Hunan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.